Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 severe or critically meta-analysis

REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine)
 
NCT02735707
RCTLopinavir/ritonavir plus hydroxychloroquinestandard of careCOVID-19 severe or criticallysome concern
29/377 safety concern
  • suggested 42 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
  • statistically significant 37 % decrease in hospital discharge with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).